SCHEMBL25933741

SCHEMBL25933741

Cc1ccc(Oc2ccc(-c3nn(C4CCN(C5CCNCC5)CC4)c4ncnc(N)c34)cc2)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BTK Q06187 12/20 0.66
SRC P12931 8/20 0.66
LCK P06239 7/20 0.66
KDR P35968 3/20 0.66
TEK Q02763 2/20 0.66
NUDT14 O95848 1/20 0.65
NUDT5 Q9UKK9 1/20 0.65
LYN P07948 1/20 0.61
EGFR P00533 3/20 0.56
ITK Q08881 1/20 0.53
CSK P41240 2/20 0.52
PIK3CD O00329 1/20 0.51
ABL1 P00519 1/20 0.51
HCK P08631 1/20 0.51
PIK3CA P42336 1/20 0.51
PIK3CB P42338 1/20 0.51
MTOR P42345 1/20 0.51
PIK3CG P48736 1/20 0.51
EPHB4 P54760 1/20 0.51
PRKDC P78527 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25466297 0.94 BTK (0.68) BTKSRCLCKKDRTEK
SCHEMBL24196855 0.93 BTK (0.66) BTKSRCLCKKDRTEK
SCHEMBL25933743 0.93 BTK (0.66) BTKSRCLCKKDRTEK
SCHEMBL22720857 0.92 BTK (0.75) BTKSRCLCKKDRTEK
SCHEMBL22720882 0.92 BTK (0.75) BTKSRCLCKKDRTEK
SCHEMBL22737441 0.92 BTK (0.75) BTKSRCLCKKDRTEK
SCHEMBL6435508 0.92 BTK (0.75) BTKSRCLCKKDRTEK
SCHEMBL30144776 0.92 BTK (0.75) BTKSRCLCKKDRTEK
SCHEMBL24196600 0.91 BTK (0.64) BTKSRCLCKKDRTEK
SCHEMBL12713456 0.89 SRC (0.64) BTKSRCLCKKDRTEK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230248833-A1 COMPOUND HAVING BTK KINASE DEGRADING ACTIVITY, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREFOR XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) 2023-08-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230248833-A1 COMPOUND HAVING BTK KINASE DEGRADING ACTIVITY, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREFOR BTK, WEE1, WEE2 BTK 1/4885SRC 142/4885LCK 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.